The Single Cell Profiling Core of the DFCI-PSOC is a virtual infrastructure led by Dr. Fan who has been serving in this role since 2012 for the current DFCI-PSOC. The core provides the capability of characterizing single cells at the omics level in order to dissect intra-clonal cellular heterogeneity, discover molecular correlates, and refine the parameters used to gauge tumor cell fitness in computational modeling. Specifically, the core will support all three projects, focused on hematologic, brain and breast cancer, respectively, by offering services to measure the transcriptome, epigenome, and proteomic signatures in single cells isolated from either `winner' clones or therapeutically resistant clones. Because fractional killing is common even within individual clones, it is highly desired to conduct single cell profiling in conjunction with computational analysis to identify molecular correlates associated with the most aggressive fraction and refine the parameters for modeling tumor cell fitness. While researchers in individual projects will carry out tracking clonal growth and molecular signature changes of each clone, the core will characterize cellular heterogeneity within individual clones, especially at the omics level, which remains challenging. The core is positioned to address this critical need and to enhance the PSOC's ability to probe cancer clonal evolution in a more systematic and granular manner. In parallel, the core is a technology innovation center that aims to develop new technology platforms (e.g., single cell methylome profiling, single cell protein secretome profiling) to enable new opportunities of scientific discoveries that cannot be achieved using the existing tools.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54CA193461-01
Application #
8866711
Study Section
Special Emphasis Panel (ZCA1-TCRB-5 (J1))
Project Start
2015-05-19
Project End
2020-04-30
Budget Start
2015-05-19
Budget End
2016-04-30
Support Year
1
Fiscal Year
2015
Total Cost
$240,083
Indirect Cost
$87,287
Name
Dana-Farber Cancer Institute
Department
Engineering (All Types)
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Ozawa, Tatsuya; Arora, Sonali; Szulzewsky, Frank et al. (2018) A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-?B. Cell Rep 23:3787-3797
Cimino, Patrick J; Kim, Youngmi; Wu, Hua-Jun et al. (2018) Increased HOXA5 expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastoma. Genes Dev 32:512-523
Stein, Shayna; Zhao, Rui; Haeno, Hiroshi et al. (2018) Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients. PLoS Comput Biol 14:e1005924
Hinohara, Kunihiko; Wu, Hua-Jun; Vigneau, Sébastien et al. (2018) KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. Cancer Cell 34:939-953.e9
Maley, Carlo C; Aktipis, Athena; Graham, Trevor A et al. (2017) Classifying the evolutionary and ecological features of neoplasms. Nat Rev Cancer 17:605-619
Dasgupta, Arko; Lim, Andrea R; Ghajar, Cyrus M (2017) Circulating and disseminated tumor cells: harbingers or initiators of metastasis? Mol Oncol 11:40-61
Gil Del Alcazar, Carlos R; Huh, Sung Jin; Ekram, Muhammad B et al. (2017) Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. Cancer Discov 7:1098-1115
Kievit, Forrest M; Wang, Kui; Ozawa, Tatsuya et al. (2017) Nanoparticle-mediated knockdown of DNA repair sensitizes cells to radiotherapy and extends survival in a genetic mouse model of glioblastoma. Nanomedicine 13:2131-2139
Pattwell, Siobhan S; Holland, Eric C (2017) Putting Glioblastoma in Its Place: IRF3 Inhibits Invasion. Trends Mol Med 23:773-776
Peinado, Héctor; Zhang, Haiying; Matei, Irina R et al. (2017) Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer 17:302-317

Showing the most recent 10 out of 36 publications